An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care for Treatment of Moderate COVID-19 in Thailand

Condition:improvement in the WHO-category ordinal scale by 2 points in moderate COVID-19 Ivermectin, Favipiravir, COVID-19, Treatment, Thailand;Ivermectin, Favipiravir, COVID-19, Treatment, ThailandIntervention:After laboratory result, intervention arm received ivermectin (at dose of 400 mcg/kg/day for 5 continuous days) plus standard of care which included favipiravir in moderately ill COVID-19 patients ,Controlled arm received standard of care alone which included favipiravir in moderately ill COVID-19 patients.;Active Comparator Drug,No Intervention Drug;Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care ,ControlledPrimary outcome:Improvement in WHO-category ordinal scale by 2 points at day 3, 7, 14, 21 after treatment WHO-category ordinal scaleCriteria:Inclusion criteria: 1. Moderate COVID-19 infection by RT-PCR technique 2. Date of onset <7 days 3. Admitted at Thammasat University hospital or Thammasat Field hospitalExclusion criteria: 1. Asymptomatic patient 2. Patient with severe symptom (on high flow nasal canular oxygen or above) 3. Pregnancy women 4. Lactating women 5. Chronic liver disease 6. Meningitis patient 7. Epilepsy who on barbiturate, benzodiazepine or valproic aside as medication 8. Who can't tolerate to oral feeding 9. Who participate other experimental drugs 10. Who had symptom that might mimicking severe drug adverse reaction (uncontrollable nausea/vomitting, liver function test 3 times UNL or above) 11. Who wish not to participate the study